



q is 1, 2, or 3;
 r is 0, 1, 2, 3, 4, 5, 6, 7, or 8;
 s is 0, 1, 2, 3, or 4;
 t is 0, 1, 2, 3, or 4;
 u is 0, 1, 2, 3, 4 or 5; and
 v is 0, 1, 2, 3, or 4.

[0004a] In another aspect, there is provided the use of a therapeutically effective amount of a compound of Formula (I), a pharmaceutically acceptable salt, solvate, stereoisomer, or isomer thereof:






Formula (I)

wherein:



A² is aryl or heteroaryl;



E is aryl, heteroaryl, carbocyclyl, or heterocyclyl;

each R¹, R², R³, and R⁴ is H;

R⁷ is alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR¹³R¹⁴), cycloalkyl, heterocyclyl, -alkylene(cycloalkyl), or -alkylene(heterocyclyl);

each R⁸ is independently selected from alkyl, cycloalkyl, heterocyclyl, halo, hydroxy, nitrile, azido, nitro, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR¹³R¹⁴), -alkylene(cycloalkyl), -alkylene(heterocyclyl), aryl, heteroaryl, -SR¹³, -SOR¹³, -SO₂R¹³, -SO₂NR¹³R¹⁴, -NR¹³R¹⁴, -NR¹³SO₂R¹⁴, -NR¹³C(O)R¹⁴, -

$\text{NR}^{13}\text{C}(\text{O})\text{OR}^{14}$, $-\text{NR}^{13}\text{C}(\text{O})\text{NR}^{13}\text{R}^{14}$, $-\text{C}(\text{O})\text{R}^{14}$, $-\text{C}(\text{O})\text{OR}^{14}$, and $-\text{C}(\text{O})\text{NR}^{13}\text{R}^{14}$; or two adjacent R^8 form a heterocyclyl ring;

each R^{13} and R^{14} is independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl; or R^{13} and R^{14} taken together form a heterocycle with the atoms to which they are attached;

Y^1 and Y^2 are O;

n is 1, 2, or 3;

m is 1;

p is 1, 2, 3, or 4;


s is 0, 1, 2, 3, or 4;

t is 0, 1, 2, 3, or 4;

u is 0, 1, 2, 3, 4 or 5; and


v is 0, 1, 2, 3, or 4, in the manufacture of a medicament for treating fibrosis, a disorder characterized by fibrosis, or a disease characterized by fibrosis.

[0004b] In another aspect, there is provided a compound of Formula (II), a pharmaceutically acceptable salt, solvate, stereoisomer, or isomer thereof:






Formula (II)

wherein:



A^2 is aryl or heteroaryl;



E is aryl, heteroaryl, carbocyclyl, heterocyclyl, or alkyl;

each R^1 , R^2 , R^3 , and R^4 is H;

R^7 is alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkylene($NR^{13}R^{14}$), cycloalkyl, heterocyclyl, -alkylene(cycloalkyl), or -alkylene(heterocyclyl);

each R^8 is independently selected from alkyl, cycloalkyl, heterocyclyl, halo, hydroxy, nitrile, azido, nitro, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene($NR^{13}R^{14}$), -alkylene(cycloalkyl), -alkylene(heterocyclyl), aryl, heteroaryl, $-SR^{13}$, $-SOR^{13}$, $-SO_2R^{13}$, $-SO_2NR^{13}R^{14}$, $-NR^{13}R^{14}$, $-NR^{13}SO_2R^{14}$, $-NR^{13}C(O)R^{14}$, $-NR^{13}C(O)OR^{14}$, $-NR^{13}C(O)NR^{13}R^{14}$, $-C(O)R^{14}$, $-C(O)OR^{14}$, and $-C(O)NR^{13}R^{14}$; or two adjacent R^8 form a heterocyclyl ring;

each R^{13} and R^{14} is independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl; or R^{13} and R^{14} taken together form a heterocycle with the atoms to which they are attached;

Y^1 and Y^2 are O;

n is 1, 2, or 3;

m is 1 or 2;

p is 1, 2, 3, or 4;

s is 0, 1, 2, 3, or 4;

t is 0, 1, 2, 3, or 4;

u is 0, 1, 2, 3, 4 or 5; and

v is 0, 1, 2, 3, or 4.

[0005] In some embodiments described above or below of a compound of Formula (I), X_1 and X_2 are N


[0006] In some embodiments described above or below of a compound of Formula (I), X_1 is CR^5 and X_2 is N.

[0007] In some embodiments described above or below of a compound of Formula (I), X_1 is N and X_2 is CR^5 .

[0008] In some embodiments described above or below of a compound of Formula (I), q is 1 and r is 0.

[0009] In some embodiments described above or below of a compound of Formula (I), A^1 is aryl.

[0010] In some embodiments described above or below of a compound of Formula (I), A^1 is




[0011] In some embodiments described above or below of a compound of Formula (I), A¹ is




[0012] In some embodiments described above or below of a compound of Formula (I), A¹ is heteroaryl.

[0013] In some embodiments described above or below of a compound of Formula (I), A² is aryl.

[0014] In some embodiments described above or below of a compound of Formula (I), A² is




[0015] In some embodiments described above or below of a compound of Formula (I), A² is



[0016] In some embodiments described above or below of a compound of Formula (I), A² is heteroaryl.


CLAIMS

1. Use of a therapeutically effective amount of a compound of Formula (I), a pharmaceutically acceptable salt, solvate, stereoisomer, or isomer thereof:






Formula (I)

wherein:



A² is aryl or heteroaryl;



E is aryl, heteroaryl, carbocyclyl, or heterocyclyl;

each R¹, R², R³, and R⁴ is H;

R⁷ is alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR¹³R¹⁴), cycloalkyl, heterocyclyl, -alkylene(cycloalkyl), or -alkylene(heterocyclyl);

each R⁸ is independently selected from alkyl, cycloalkyl, heterocyclyl, halo, hydroxy, nitrile, azido, nitro, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR¹³R¹⁴), -alkylene(cycloalkyl), -alkylene(heterocyclyl), aryl, heteroaryl, -SR¹³, -SOR¹³, -SO₂R¹³, -SO₂NR¹³R¹⁴, -NR¹³R¹⁴, -NR¹³SO₂R¹⁴, -NR¹³C(O)R¹⁴, -NR¹³C(O)OR¹⁴, -NR¹³C(O)NR¹³R¹⁴, -C(O)R¹⁴, -C(O)OR¹⁴, and -C(O)NR¹³R¹⁴; or two adjacent R⁸ form a heterocyclyl ring;

each R¹³ and R¹⁴ is independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl; or R¹³ and R¹⁴ taken together form a heterocycle with the atoms to which they are attached;

Y¹ and Y² are O;

n is 1, 2, or 3;

m is 1;




p is 1, 2, 3, or 4;


s is 0, 1, 2, 3, or 4;









t is 0, 1, 2, 3, or 4;









u is 0, 1, 2, 3, 4 or 5; and









v is 0, 1, 2, 3, or 4, in the manufacture of a medicament for treating fibrosis, a disorder characterized by fibrosis, or a disease characterized by fibrosis.









2. The use of claim 1, wherein A^2 is .
3. The use of claim 1, wherein A^2 is pyridine, pyrazine, pyrimidine, pyridazine, or triazine.
4. The use of any one of claims 1-3, wherein C is ; and R^7 is alkyl.
5. The use of any one of claims 1-3, wherein C is ; and R^7 is alkyl.
6. The use of any one of claims 1-5, wherein E is cycloalkyl.
7. The use of claim 6, wherein E is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
8. The use of any one of claims 1-5, wherein E is heterocyclyl.
9. The use of any one of claims 1-5, wherein E is .
10. The use of any one of claims 1-5, wherein E is heteroaryl.
11. The use of any one of claims 1-10, wherein p is 1, 2, or 3.
12. The use of claim 11, wherein p is 1.
13. The use of claim 1, wherein the compound is selected from:































14. The use of any one of claims 1-13, wherein the fibrosis is liver fibrosis, idiopathic pulmonary fibrosis, kidney fibrosis, or cardiac fibrosis.
15. The use of claim 14, wherein the liver fibrosis is associated with the later stages of alcoholic or nonalcoholic liver cirrhosis.
16. The use of claim 14, wherein the fibrosis is idiopathic pulmonary fibrosis.
17. The use of any one of claims 1-13, wherein the disease or disorder characterized by fibrosis is a chronic autoimmune disease.
18. The use of claim 17, wherein the chronic autoimmune disease is rheumatoid arthritis, scleroderma, Crohn's disease or systemic lupus erythematosus.
19. The use of claim 18, wherein the chronic autoimmune disease is scleroderma.
20. The use of any one of claims 1-13, wherein the fibrosis is keloid formation resulting from abnormal wound healing.
21. The use of any one of claims 1-13, wherein the fibrosis occurs after organ transplantation.
22. A compound of Formula (II), a pharmaceutically acceptable salt, solvate, stereoisomer, or isomer thereof:






Formula (II)

wherein:



A² is aryl or heteroaryl;



E is aryl, heteroaryl, carbocyclyl, heterocyclyl, or alkyl;

each R¹, R², R³, and R⁴ is H;

R⁷ is alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkylene(NR¹³R¹⁴), cycloalkyl, heterocyclyl, -alkylene(cycloalkyl), or -alkylene(heterocyclyl);

each R⁸ is independently selected from alkyl, cycloalkyl, heterocyclyl, halo, hydroxy, nitrile, azido, nitro, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR¹³R¹⁴), -alkylene(cycloalkyl), -alkylene(heterocyclyl), aryl, heteroaryl, -SR¹³, -SOR¹³, -SO₂R¹³, -SO₂NR¹³R¹⁴, -NR¹³R¹⁴, -NR¹³SO₂R¹⁴, -NR¹³C(O)R¹⁴, -NR¹³C(O)OR¹⁴, -NR¹³C(O)NR¹³R¹⁴, -C(O)R¹⁴, -C(O)OR¹⁴, and -C(O)NR¹³R¹⁴; or two adjacent R⁸ form a heterocyclyl ring;

each R¹³ and R¹⁴ is independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl; or R¹³ and R¹⁴ taken together form a heterocycle with the atoms to which they are attached;

Y¹ and Y² are O;

n is 1, 2, or 3;

m is 1 or 2;


p is 1, 2, 3, or 4;

s is 0, 1, 2, 3, or 4;


t is 0, 1, 2, 3, or 4;


u is 0, 1, 2, 3, 4 or 5; and

v is 0, 1, 2, 3, or 4.

23. The compound of claim 22, wherein A² is .

24. The compound of claim 22, wherein A² is pyridine, pyrazine, pyrimidine, pyridazine, or triazine.


25. The compound of any one of claims 22-24, wherein C is .

26. The compound of any one of claims 22-24, wherein C is .


27. The compound of any one of claims 22-26, wherein E is cycloalkyl.


28. The compound of claim 27, wherein E is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

29. The compound of any one of claims 22-26, wherein E is heterocyclyl.

30. The compound of any one of claims 22-26, wherein E is .

31. The compound of any one of claims 22-26, wherein E is heteroaryl.


32. The compound of any one of claims 22-31, wherein D is .









33. The compound of any one of claims 22-31, wherein D is .









34. The compound of any one of claims 22-33, wherein p is 1, 2, or 3.









35. The compound of claim 34, wherein p is 1.









36. The compound of claim 22, wherein the compound is selected from:




































37. A pharmaceutical composition comprising a compound of any one of claims 22-36, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isomer thereof, and a pharmaceutically acceptable excipient.